PLATELET CONCENTRATION SYSTEMS MARKET ANALYSIS

Platelet Concentration Systems Market, By Technology (Apheresis Technology, Single Spin Technology, Double Spin Technology), By Application (Orthopedics, Cosmetic Surgery and Dermatology, Neurology, Cardiology, and Others (Ophthalmology and Others)), By End User (Hospital, Blood Banks and Transfusion Centers, Ambulatory Surgical Centers, and Others (Research Laboratories, Stand-alone Processing Facilities)), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

New product launches

In 2021, Royal Biologics, an ortho-biologics company focused on autologous and live cellular solutions, announced the U.S. FDA 510K approval of its Maxx-PRP concentration system. Maxx-PRP is a patented next-generation concentration device that can be used to concentrate autologous whole blood for the safe and rapid preparation of platelet-rich plasma to use point of care for mixing with autograft and/or allograft to improve handling characteristics.
In 2018, APEX Biologix launched a new XCELL PRP system. The XCELL PRP system has a specialized concentrating device that helps to shorten the total processing time and reduce human error compared to other systems.
In August 2019, Healeon Medical, Inc., a wholly owned subsidiary of Bimini Health Tech, commercial-stage medical device and biologics company, received the U.S. FDA 510 (K) clearance approval for its Healeon Duet (BK200449), a novel blood separation system for platelet rich plasma (PRP) preparation

Acquisition and partnerships

In October 2018, Arthrex Inc., a global medical device company, built a new state-of-the-art surgical device and implant manufacturing facility in Anderson County, South Carolina, U.S This investment is a part of Arthrex’s global expansion plan to support the development of new and innovative products that help surgeons treat their patients better.